Nurexone Biologic Inc
F:J90
Nurexone Biologic Inc
Total Receivables
Nurexone Biologic Inc
Total Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Nurexone Biologic Inc
F:J90
|
Total Receivables
$52k
|
CAGR 3-Years
73%
|
CAGR 5-Years
12%
|
CAGR 10-Years
N/A
|
|
|
Enerflex Ltd
TSX:EFX
|
Total Receivables
CA$578m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
13%
|
CAGR 10-Years
6%
|
|
|
T
|
TerraVest Industries Inc
TSX:TVK
|
Total Receivables
CA$192m
|
CAGR 3-Years
23%
|
CAGR 5-Years
35%
|
CAGR 10-Years
17%
|
|
|
CES Energy Solutions Corp
TSX:CEU
|
Total Receivables
CA$529.1m
|
CAGR 3-Years
3%
|
CAGR 5-Years
27%
|
CAGR 10-Years
12%
|
|
|
Secure Energy Services Inc
TSX:SES
|
Total Receivables
CA$452m
|
CAGR 3-Years
0%
|
CAGR 5-Years
26%
|
CAGR 10-Years
12%
|
|
|
H
|
HydroGraph Clean Power Inc
CNSX:HG
|
Total Receivables
$89.1k
|
CAGR 3-Years
38%
|
CAGR 5-Years
80%
|
CAGR 10-Years
N/A
|
|
Nurexone Biologic Inc
Glance View
NurExone Biologic, Inc. is a pharmaceutical company, which engages in the development and commercialization of biological extracellular vesicles (EV)-based technology drug platform. The company is headquartered in Edmonton, Alberta. The company went IPO on 2012-05-08. The firm is developing a biological extracellular vesicles (EV)-based technology drug platform. The technology drug platform offers treatment for reversing paralysis and improving the life of patients following spinal cord injury using bio-guided exosomes (membrane-bound extracellular vesicles) loaded with modified small interfering RNA (siRNA) sequence. Its technology is used to treat various conditions, such as spinal cord injury, traumatic brain injury, and other brain and neurological indications. The firm also has developed exosome manufacturing process. The company is also focused on exosome research, management of clinical studies and commercialization of the technology for different indications, not limited to the central nervous system.
See Also
What is Nurexone Biologic Inc's Total Receivables?
Total Receivables
52k
USD
Based on the financial report for Dec 31, 2024, Nurexone Biologic Inc's Total Receivables amounts to 52k USD.
What is Nurexone Biologic Inc's Total Receivables growth rate?
Total Receivables CAGR 5Y
12%
Over the last year, the Total Receivables growth was 0%. The average annual Total Receivables growth rates for Nurexone Biologic Inc have been 73% over the past three years , 12% over the past five years .
